TY - JOUR
T1 - CD20-negative large-cell lymphoma with plasmablastic features
T2 - A clinically heterogenous spectrum in both HIV-positive and -negative patients
AU - Teruya-Feldstein, J.
AU - Chiao, E.
AU - Filippa, D. A.
AU - Lin, O.
AU - Comenzo, R.
AU - Coleman, M.
AU - Portlock, C.
AU - Noy, A.
PY - 2004/11
Y1 - 2004/11
N2 - Background: Plasmablastic lymphoma (PBL) has been described as a rapidly progressive and almost invariably fatal CD20- VS38c+ diffuse large-cell lymphoma with plasmablastic features, almost exclusively involving the jaw and oral mucosa in HIV-positive patients. Methods: From 2001 to 2003 we evaluated 12 men with PBL, and report the pathology, clinical findings, treatment and outcome. Six of 12 were HIV-positive while among the others, one was post-renal transplant, one had ulcerative colitis and four had no known immunodeficiency. Results: Tumor growth pattern, in general, showed cohesiveness and a starry-sky pattern; the morphology varied from typical plasmablastic to centroblastic cells. Partial immunophenotypes were (+/total): CD138, 11 of 12 (91.7%); MIB1 10 of 11 (4+, range 75-95%); p63/VS38c, nine of 10 (90%); EBV, eight of 11 (73%); LCA(CD45), two of 12 (16.7%); HHV8/LANA, zero of 10; ALK, zero of seven; and CD20, zero of 12. Three had stage IE and nine stage IV disease. Nine of 12 had an intermediate/high International Prognostic Index or high-risk disease. Computed tomography and positron emission tomography scan in four of 12 revealed extensive bone metastases. Seven of 12 patients are alive with no evidence of disease at a median follow-up of 15 months (range 7-27+). Of the HIV-positive patients, five of six are alive with a median follow-up of 17 months. Conclusions: It appears that PBL are heterogenous in terms of clinical presentation and morphology. The outcome presented here is superior to that originally reported.
AB - Background: Plasmablastic lymphoma (PBL) has been described as a rapidly progressive and almost invariably fatal CD20- VS38c+ diffuse large-cell lymphoma with plasmablastic features, almost exclusively involving the jaw and oral mucosa in HIV-positive patients. Methods: From 2001 to 2003 we evaluated 12 men with PBL, and report the pathology, clinical findings, treatment and outcome. Six of 12 were HIV-positive while among the others, one was post-renal transplant, one had ulcerative colitis and four had no known immunodeficiency. Results: Tumor growth pattern, in general, showed cohesiveness and a starry-sky pattern; the morphology varied from typical plasmablastic to centroblastic cells. Partial immunophenotypes were (+/total): CD138, 11 of 12 (91.7%); MIB1 10 of 11 (4+, range 75-95%); p63/VS38c, nine of 10 (90%); EBV, eight of 11 (73%); LCA(CD45), two of 12 (16.7%); HHV8/LANA, zero of 10; ALK, zero of seven; and CD20, zero of 12. Three had stage IE and nine stage IV disease. Nine of 12 had an intermediate/high International Prognostic Index or high-risk disease. Computed tomography and positron emission tomography scan in four of 12 revealed extensive bone metastases. Seven of 12 patients are alive with no evidence of disease at a median follow-up of 15 months (range 7-27+). Of the HIV-positive patients, five of six are alive with a median follow-up of 17 months. Conclusions: It appears that PBL are heterogenous in terms of clinical presentation and morphology. The outcome presented here is superior to that originally reported.
KW - EBV-positive
KW - HIV-positive/negative patients
KW - Plasmablastic lymphoma
UR - http://www.scopus.com/inward/record.url?scp=9444231808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9444231808&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdh399
DO - 10.1093/annonc/mdh399
M3 - Article
C2 - 15520070
AN - SCOPUS:9444231808
SN - 0923-7534
VL - 15
SP - 1673
EP - 1679
JO - Annals of Oncology
JF - Annals of Oncology
IS - 11
ER -